Novo Nordisk’s new oral formulation of semaglutide 25 mg (Wegovy in a pill) produced a 16.6% average weight loss among adults with obesity, according to results from a newly published clinical study. The once-daily pill, developed as an…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply